Siegall is moving on after an unhappy exit from Seagen with a new role at another company with a novel targeted oncology platform.

The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.

Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.

The French major is planning a Phase II trial of KT-474 in atopic dermatitis and hidradenitis suppurativa after the asset fared well in a small Phase I trial, although some analysts remain skeptical.